141 related articles for article (PubMed ID: 27790745)
1. N-Ras mutation in vemurafenib-associated expanding melanocytic nevus.
Harada K; Kato Y; Maeda T; Yoshida M; Irisawa R; Nagao T; Tsuboi R
J Dermatol; 2017 May; 44(5):e101-e102. PubMed ID: 27790745
[No Abstract] [Full Text] [Related]
2. Vogt-Koyanagi-Harada disease-like uveitis induced by vemurafenib for metastatic cutaneous malignant melanoma.
Fusumae T; Kamiya K; Maekawa T; Komine M; Murata S; Inoda S; Takahashi R; Kawashima H; Ohtsuki M
J Dermatol; 2018 Jun; 45(6):e159-e160. PubMed ID: 29314171
[No Abstract] [Full Text] [Related]
3. Evolution of melanocytic nevi under vemurafenib, followed by combination therapy with dabrafenib and trametinib for metastatic melanoma.
Giurcaneanu C; Nitipir C; Popa LG; Forsea AM; Popescu I; Bumbacea RS
Acta Dermatovenerol Croat; 2015; 23(2):114-21. PubMed ID: 26228819
[TBL] [Abstract][Full Text] [Related]
4. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
5. A Case of Perforating Folliculitis Induced by Vemurafenib.
Shiraishi K; Masunaga T; Tohyama M; Sayama K
Acta Derm Venereol; 2019 Feb; 99(2):230-231. PubMed ID: 30281138
[No Abstract] [Full Text] [Related]
6. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
7. Case of severe acneiform eruptions associated with the BRAF inhibitor vemurafenib.
Ansai O; Fujikawa H; Shimomura Y; Abe R
J Dermatol; 2017 Mar; 44(3):e15-e16. PubMed ID: 27511106
[No Abstract] [Full Text] [Related]
8. Agminated melanocytic nevus status post dabrafenib therapy for metastatic melanoma.
Agulló A; Hinds B; Santesteban R; Mitxelena JM; Yanguas I
Dermatol Online J; 2016 Jul; 22(7):. PubMed ID: 27617734
[TBL] [Abstract][Full Text] [Related]
9. Neutrophilic panniculitis with vasculitis in a melanoma patient treated with vemurafenib: a case report and its management.
Ueno M; Namiki T; Inui K; Hanafusa T; Miura K; Yokozeki H
Int J Dermatol; 2017 Aug; 56(8):e163-e165. PubMed ID: 28244062
[No Abstract] [Full Text] [Related]
10. Acantholytic dyskeratotic acanthoma: a possible skin adverse event of vemurafenib treatment.
Komori T; Otsuka A; Kaku Y; Honda T; Kabashima K
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):e474-e475. PubMed ID: 28426905
[No Abstract] [Full Text] [Related]
11. Multiple eruptive squamous cell carcinomas: a possible clinical sign in melanoma patients treated with vemurafenib.
Jovic A; Tiodorovic D; Popovic D; Vidovic N; Zlatanovic Z; Cekic S; Kocic H; Damiani G
Eur J Dermatol; 2021 Apr; 31(2):279-280. PubMed ID: 34001482
[No Abstract] [Full Text] [Related]
12. Acquired dysplastic melanocytic nevi and cutaneous melanoma: precursors and prevention.
Rhodes AR
Ann Intern Med; 1985 Apr; 102(4):546-8. PubMed ID: 3977199
[No Abstract] [Full Text] [Related]
13. Aggressive melanoma in an infant with congenital melanocytic nevus syndrome and multiple, NRAS and BRAF mutation-negative nodules.
de la Rosa Carrillo D; Vindenes H; Kinsler VA; Rønnestad A; Ringstad G; Müller LO; Tafjord S; Tønseth KA; Kvamme B; Clausen OPF
Pediatr Dermatol; 2018 Sep; 35(5):e281-e285. PubMed ID: 29999207
[TBL] [Abstract][Full Text] [Related]
14. Malignant melanoma arising from an NRAS-mutated medium-sized congenital melanocytic nevus.
Kiyohara T; Takata M; Itoh H; Kawami K; Ido H; Ishida H; Kumakiri M
J Dermatol; 2012 Dec; 39(12):1034-5. PubMed ID: 22452623
[No Abstract] [Full Text] [Related]
15. Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of endoplasmic reticulum stress-induced apoptosis for melanoma therapy.
Hiscutt EL; Hill DS; Martin S; Kerr R; Harbottle A; Birch-Machin M; Redfern CP; Fulda S; Armstrong JL; Lovat PE
J Invest Dermatol; 2010 Sep; 130(9):2250-8. PubMed ID: 20520630
[TBL] [Abstract][Full Text] [Related]
16. Transcriptome sequencing of melanocytic nevi and melanomas from Grm1 transgenic mice to determine melanoma driver mutations.
de Jel MM; Engelmann JC; Kunz M; Schiffner S; Kuphal S; Bosserhoff AK
Pigment Cell Melanoma Res; 2014 Jul; 27(4):678-80. PubMed ID: 24661573
[No Abstract] [Full Text] [Related]
17. High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib.
Göppner D; Müller J; Krüger S; Franke I; Gollnick H; Quist SR
Acta Derm Venereol; 2014 Sep; 94(5):517-20. PubMed ID: 24531394
[TBL] [Abstract][Full Text] [Related]
18. Primary cutaneous melanoma arising in agminated melanocytic nevi: CDKN2A and CDK4 mutation screening.
Rezze GG; Leon A; Silva DC; Neves RI; Molina GC; Carraro DM; Landman G; Duprat JP
Acta Derm Venereol; 2012 Jan; 92(1):98-9. PubMed ID: 21710107
[No Abstract] [Full Text] [Related]
19. [Severe panuveitis in a metastatic cutaneous melanoma patient treated with vemurafenib].
Boiché M; Conart JB; Angioi-Duprez K
J Fr Ophtalmol; 2018 Jun; 41(6):e291-e292. PubMed ID: 29908650
[No Abstract] [Full Text] [Related]
20. Vemurafenib-induced plantar hyperkeratosis.
Bashline BR; Bedocs PM
Cutis; 2018 Sep; 102(3):E19-E21. PubMed ID: 30372722
[No Abstract] [Full Text] [Related]
[Next] [New Search]
